Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia

被引：13

作者：

Islam, Nazmul ^{[1
]}

Lau, Colleen ^{[2
,3
,4
]}

Leeb, Alan ^{[5
]}

Mills, Deborah ^{[3
,4
]}

Furuya-Kanamori, Luis ^{[6
]}

机构：

[1] Qatar Univ, Coll Hlth Sci, Dept Publ Hlth, QU Hlth, POB 2713, Doha, Qatar

[2] Univ Queensland, Fac Med, Sch Publ Hlth, Herston, Qld, Australia

[3] Travel Med Alliance, Dr Deb Travel Doctor, Brisbane, Qld, Australia

[4] Australian Natl Univ, Coll Hlth & Med, Res Sch Populat Hlth, Canberra, ACT, Australia

[5] Illawarra Med Ctr, Perth, WA, Australia

[6] Univ Queensland, Fac Med, UQ Ctr Clin Res, Herston, Qld, Australia

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2022年 / 18卷 / 01期

基金：

英国医学研究理事会;

关键词：

Immunization; tolerability; safety; SmartVax; vaccination; EVENTS FOLLOWING IMMUNIZATION; IMMUNOGENICITY; TOLERABILITY; IMOJEV(R); BLIND; IC51;

D O I：

10.1080/21645515.2021.2020573

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Limited information is available about post-marketing safety of Japanese encephalitis (JE) vaccines. Using data from SmartVax, an active surveillance system for monitoring vaccine safety, adverse events following immunizations (AEFIs) were compared between the two JE vaccines available in Australia (a chimeric live attenuated vaccine [Imojev] and a Vero cell-derived inactivated vaccine [JEspect]). Data from 2756 patients (1855 Imojev and 901 JEspect) were included. Overall (7.0%), systemic (2.8%), and local (1.9%) AEFIs were uncommon. There were no significant differences in the odds of overall (OR = 1.27; 95%CI: 0.91-1.77), systemic (OR = 1.23; 95%CI: 0.74-2.06), or local (OR = 1.20; 95%CI: 0.65-2.22) AEFIs with Imojev compared to JEspect. There was an increase in odds of overall AEFI in patients aged <5 years (OR = 2.39; 95%CI: 1.10-5.19) compared to those aged >50 years. Both JE vaccines available in Australia are safe and well tolerated. Odds of AEFIs were age-dependent, young children should be carefully observed for AEFIs after vaccination.

引用

页数：8

共 35 条

[31] Epidemiology of viral encephalitis in 2011 [J].

Stahl, J. -P. ;

Mailles, A. ;

Dacheux, L. ;

Morand, P. .

MEDECINE ET MALADIES INFECTIEUSES, 2011, 41 (09) :453-464

[32] Safety and immunogenicity of a Vero-cell-derived,inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial [J].

Tauber, E. ;

Kollaritsch, H. ;

Korinek, M. ;

Rendi-Wagner, P. ;

Jilma, B. ;

Firbas, C. ;

Schranz, S. ;

Jong, E. ;

Klingler, A. ;

Dewasthaly, S. ;

Klade, C. S. .

LANCET, 2007, 370 (9602) :1847-1853

[33] Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials [J].

Torresi, Joseph ;

McCarthy, Karen ;

Feroldi, Emmanuel ;

Meric, Claude .

VACCINE, 2010, 28 (50) :7993-8000

[34]

Tsai Theodore F., 2000, Vaccine, V18, P1, DOI 10.1016/S0264-410X(00)00037-2

[35] Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016 [J].

Walker, William L. ;

Hills, Susan L. ;

Miller, Elaine R. ;

Fischer, Marc ;

Rabe, Ingrid B. .

VACCINE, 2018, 36 (29) :4369-4374

← 1 2 3 4 →